top of page

CYTORA Strengthens U.S. Presence Following Strategic Florida Health-Tech Engagements

8 January 2026

Following the announcement of our landmark partnership with Made Scientific and Zeo ScientifIX, CYTORA’s CEO, Dr. Yona Geffen, took the stage at the Mini MIXiii Symposium in Miami to present our uniqe innovative off-the-shelf stem cell technology.

​

Our CEO, Dr Yona Geffen, presented CYTORA’s unique allogeneic stem cell therapy platform at the Mini MIXiii Symposium which show cases leading Israeli Health-Tech startups. 

Cytora bottom logo

MENU

Cytora’s patented platform technology is based on the discovery of a novel and unique stem cell population in the human oral mucosa (hOMSC), the origin of which is the embryonic nervous system. hOMSC are endowed with properties of neural crest, neural and mesenchymal stem cells. Cytora’s products are allogeneic, off-the-shelf, easily scalable, with a very competitive cost of goods (COG). The products were found to be safe and effective in early phase clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

Our products have high potential for treating complicated multifactorial diseases such as chronic and neurodegenerative diseases, incurable wounds and autoimmune diseases.

ABOUT US

TECHNOLOGY

PIPELINE

TEAM

PUBLICATIONS

NEWS AND EVENTS

CONTACT US

CONTACT US

info@cytorastem.com

© 2022 Cytora. All rights reserved.

bottom of page